Edition:
India

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

4.05USD
22 Nov 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.05
Open
$4.10
Day's High
$4.10
Day's Low
$3.80
Volume
125,051
Avg. Vol
84,452
52-wk High
$6.45
52-wk Low
$2.58

Latest Key Developments (Source: Significant Developments)

Sabby Management, LLC reports 7.73 pct passive stake in Adamis Pharmaceuticals
Wednesday, 10 Aug 2016 

Adamis Pharmaceuticals Corp : Sabby Management, LLC reports 7.73 pct passive stake in Adamis Pharmaceuticals as of August 3, 2016 - SEC Filing Source - http://bit.ly/2aJYpKi Further company coverage: [ADMP.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

CVI Investments reports 5.5 pct passive stake in Adamis Pharmaceuticals
Monday, 8 Aug 2016 

:CVI Investments Inc reports a passive stake of 5.5 percent in Adamis Pharmaceuticals Corp as of July 29, 2016 - SEC Filing.  Full Article

Adamis Pharmaceuticals announces $11.1 mln offering
Friday, 29 Jul 2016 

Adamis Pharmaceuticals Corp : Adamis Pharmaceuticals announces $11.1 million registered direct offering . Estimates that net offering proceeds, after deducting placement agent fees, will be approximately $10.3 million .Adamis Pharmaceuticals Corp says offering was priced at $3.095 per unit.  Full Article

Adamis Pharmaceuticals- private placement of about $5 mln
Tuesday, 12 Jul 2016 

Adamis Pharmaceuticals Corp : Adamis Pharmaceuticals announces private placement . Says received gross cash proceeds of approximately $5 million .Says issued 1.7 million shares of series A-2 convertible preferred stock to a small number of institutional investors.  Full Article

Adamis receives response letter from FDA for its epinephrine syringe
Monday, 6 Jun 2016 

Adamis Pharmaceuticals : FDA indicated that in order to support approval of product, company must expand its human factors study . Believes that it can finalize study protocols with FDA and complete additional testing within a "relatively short period of time" . Believes that it can submit data back to FDA sometime in second half of 2016 .Receives complete response letter from FDA for its epinephrine pre-filled syringe NDA.  Full Article

Adamis Pharmaceuticals Completes Acquisition of US Compounding
Tuesday, 12 Apr 2016 

Adamis Pharmaceuticals Corporation:completed its previously announced acquisition (the "Acquisition") of US Compounding, Inc. ("USC").Upon the closing of this transaction, USC has become a wholly-owned subsidiary of Adamis.  Full Article

Adamis Pharmaceuticals announces NDA Resubmission of Epinephrine Pre-Filled Syringe Application to FDA
Monday, 7 Dec 2015 

Adamis Pharmaceuticals Corporation:Announced the resubmission of the Company's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis.Resubmission is intended to address the issues raised by the FDA in the agency's March 2015 Complete Response Letter (CRL).  Full Article

Adamis wins U.S. approval to sell EpiPen rival, shares soar

Adamis Pharmaceuticals Corp said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan NV's widely used EpiPen, sending its shares up more than 50 percent.